AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04254861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)
Description: A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured.
Study NCT04254861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simplified Papilla Preservation Flap (SPPF) and GTR
Description: A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
Study NCT06085378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary Kallidinogenase for injection
Description: The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
Study NCT06085378 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
Study NCT01685034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergy immunotherapy (allergy shots)
Study NCT06308224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified-Otago Exercises
Description: Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking.
Study NCT06308224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-Chi Exercises
Description: Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes.
Study NCT04944420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health enSuite Caregivers
Description: Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access.
Study NCT05456269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisantrene Dihydrochloride (high dose)
Description: Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
Study NCT05456269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisantrene Dihydrochloride (low dose)
Description: IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
Study NCT05456269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Hydrochloride
Description: Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
Study NCT05456269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and cedazuridine
Description: PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
Study NCT05899985 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System
Description: FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry).
Study NCT05372094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Hearing Aid
Description: Commercially available hearing aid with various noise reduction strengths
Study NCT05633199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
Study NCT05689268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EUS-PPG and HVPG
Description: EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed.
Study NCT06187480 — intervention group
Intervention type: PROCEDURE
Intervention: total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)
Description: The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
Study NCT05703204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF32101
Description: The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
Study NCT05493124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manpixiao
Description: A traditional Chinese medicine composition
Study NCT05493124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Other drugs that may have therapeutic effects
Study NCT05844748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes education with motivational interview technique
Description: Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
Study NCT04975620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine needle biopsy
Description: Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
Study NCT04636996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: artificial intelligence assisted follow-up
Description: We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
Study NCT04636996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificial intelligence assisted follow-up
Description: We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
Study NCT05890209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring device
Description: A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
Study NCT06397092 — intervention group
Intervention type: PROCEDURE
Intervention: transapical beating-heart septal myectomy
Description: The patients with hypertrophic cardiomyopathy undergoing TA-BSM
Study NCT05839925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II
Description: The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
Study NCT06317727 — intervention group
Intervention type: DEVICE
Intervention: Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)
Description: The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
Study NCT05110131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device for performing biopsy via electromagnetic navigation bronchoscopy
Description: Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
Study NCT04380649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New headset prototype
Description: creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
Study NCT01716676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine CPAP monitoring (webpage and televisit)
Study NCT01716676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP monitoring
Study NCT05487755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20Mg Oral Tablet
Description: Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
Study NCT05487755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG Oral Tablet
Description: Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
Study NCT05338372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two days forest therapy
Description: Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
Study NCT05338372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three days forest therapy
Description: Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
Study NCT04714281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dialyser
Description: Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
Study NCT06318039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel program
Description: Applying new training method; the Nordic hamstring exercise
Study NCT06318039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novel program
Description: Applying new training method; the Nordic hamstring exercise
Study NCT06318039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional program
Description: Conventional rehabilitation training administered
Study NCT05595941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele-yoga
Description: Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant.
Study NCT05252871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Description: Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Study NCT06318039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program
Description: Conventional rehabilitation training administered
Study NCT05252871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Description: Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Study NCT04836624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Co-designing of personalised aids of daily living
Description: In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. .
Study NCT06614608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% ASKC200
Description: 5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
Study NCT06614608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% ASKC200
Description: 1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
Study NCT05282121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)
Study NCT05282121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT06059950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Flow Program
Description: The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
Study NCT06201520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual acupuncture
Description: manual acupuncture
Study NCT06201520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: laser acupuncture therapy
Study NCT06201520 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture
Description: sham laser acupuncture
Study NCT06201520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist splint
Description: wear wrist splint at night
Study NCT06201520 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: wrist splint
Description: wear wrist splint at night
Study NCT06223529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Instrumental Music Performance
Description: Exercises using musical instruments to improve hemiparetic hand and arm function
Study NCT05943652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological examination
Description: A neurological examination following a protocol to detect positive signs of functional neurological disorders.
Study NCT05943652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anamnesis
Description: A standardized question about the patient´s history. The response time is measured.~Question: Could you tell me about the problems with the movement disorder you are experiencing?
Study NCT05943652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological testing
Description: Neuropsychological cognitive testing including:~* Montreal Cognitive Assessment (MOCA)~* Rey-Osterrieth Complex Figure Test (ROCFT)~* Wechsler Memory Scale IV~* Comprehensive Trail Making Test (CTMT)~* semantic and phonematic fluency tests
Study NCT05943652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: * Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)
Study NCT06616038 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Given the observational nature of the study, the intervention is a simple data collection
Study NCT06677879 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Lumpectomy group: The total dose was 40.05Gy (RBE) , 2.67Gy (RBE) per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy (RBE) , 2.66Gy (RBE) per fraction with 16 fractions. Once a day, five times a week.
Study NCT06677879 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon radiotherapy
Description: Lumpectomy group: The total dose was 40.05Gy, 2.67Gy per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy, 2.66Gy per fraction with 16 fractions. Once a day, five times a week.
Study NCT06678165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-204
Description: The intervention group will receive YOLT-204 on day0
Study NCT06678204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized illustrated pamphlets
Description: Participants in the control group received traditional text-based pamphlets covering similar self-care information for RT. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
Study NCT05540522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza modRNA vaccine
Description: Quadrivalent influenza modRNA vaccine (single dose)